Evidence map›Paper›PMID 33081233›Full record

ReviewInternational journal of molecular sciences2020

Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy.

Lin Jiang, Jialiang Liang, Wei Huang, Zhichao Wu, Christian Paul, Yigang Wang

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Cell Programming for Cardiovascular Disease Modeling and Therapy.International journal of molecular sciences · 2023
    Article
  5. Article
  6. Cardiac microRNAs: diagnostic and therapeutic potential.Archives of medical science : AMS · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lin JiangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0529, USA.
Jialiang LiangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0529, USA.ORCID 0000-0001-8033-741X
Wei HuangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0529, USA.
Zhichao WuDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0529, USA.
Christian PaulDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0529, USA.
Yigang WangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0529, USA.
University of Cincinnati Medical Center · US

Funding

CRISPR-induced cardiovascular progenitor cells to repair myocardial infarctionR01HL157456 · NHLBI · UNIVERSITY OF CINCINNATI · PI LIANG, JIALIANG, WANG, YIGANG · 2021 to 2024
$2.4M
Autologous Cardiomyocytes from Masseter Muscles to Repair Myocardial Infarction (MI)R01HL136025 · NHLBI · UNIVERSITY OF CINCINNATI · PI DAVIDSON, W SEAN, WANG, YIGANG · 2017 to 2020
$1.8M
IGF-2R is a new therapeutic target for cardiac ischemia-reperfusion injuryR01HL143490 · NHLBI · UNIVERSITY OF CINCINNATI · PI WANG, YIGANG · 2019 to 2022
$1.6M
NHLBI NIH HHS R01 HL143490NHLBI NIH HHS R01 HL157456NIH HHS R01HL136025NIH HHS R01 HL143490
6 · The paper itself

Abstract

Limited adult cardiac cell proliferation after cardiovascular disease, such as heart failure, hampers regeneration, resulting in a major loss of cardiomyocytes (CMs) at the site of injury. Recent studies in cellular reprogramming approaches have provided the opportunity to improve upon previous techniques used to regenerate damaged heart. Using these approaches, new CMs can be regenerated from differentiation of iPSCs (similar to embryonic stem cells), the direct reprogramming of fibroblasts [induced cardiomyocytes (iCMs)], or induced cardiac progenitors. Although these CMs have been shown to functionally repair infarcted heart, advancements in technology are still in the early stages of development in research laboratories. In this review, reprogramming-based approaches for generating CMs are briefly introduced and reviewed, and the challenges (including low efficiency, functional maturity, and safety issues) that hinder further translation of these approaches into a clinical setting are discussed. The creative and combined optimal methods to address these challenges are also summarized, with optimism that further investigation into tissue engineering, cardiac development signaling, and epigenetic mechanisms will help to establish methods that improve cell-reprogramming approaches for heart regeneration.

Indexed as

AnimalsCellular Reprogramming TechniquesHeartHeart DiseasesHumansRegenerationStem Cell TransplantationTissue Engineeringcardiac differentiationcardiomyocytedirect reprogrammingfibroblastsHeart regenerationinduced pluripotent stem cells

Identifiers

PMID33081233
PMCPMC7589611
OpenAlexW3093243763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.